The impact of haemophilus influenza serotype b resurgence on the epidemiology of childhood invasive Haemophilus influenzae disease in England and WalesArchived
The authors describe the epidemiology of invasive Hib and nontype b H. influenzae infections in children below 15 years of age in the United Kingdom from 1994 until 2008, and show that the resurgence in Hib disease during the years 1999-2003 did not affect the epidemiology of invasive nontype b H. influenzae disease in children, which provides further support against serotype replacement. However, the small yet significant year-on-year rise in nontype b H. Influenza incidence deserves further study.
Ladhani SN, Ramsay M, Slack MPE. Pediatr Infect Dis J 2011; 30(10): 893-5
The UK introduced Hib vaccination in 1992, which resulted to a 90% decline in invasive Hib disease across all age groups within 2 years through direct protection and herd immunity. However, in 1999 the number of cases resurged, mainly due to a greater than expected decline in protective Hib antibody concentrations after primary infant immunization, waning of herd immunity offered by the initial catch-up campaign, and the use of a less immunogenic Hib combination vaccine containing acellular pertussis in 2000–2001.
Extensively drug-resistant gonorrhoea: risk of further dissemination within and across Europe
1 Apr 2019 - ECDC comment on the study 'Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018' by Eyre et al. in the Eurosurveillance edition of 7 March 2019.
Conclusions of the twentieth IHR Emergency Committee do not change the ECDC risk assessment for Europe concerning polio
11 Mar 2019 - Statement of the twentieth IHR Emergency Committee Regarding the International Spread of Poliovirus, 1 March 2019
WHO recommendations for influenza virus vaccine composition for the 2019–2020 northern hemisphere season
1 Mar 2019 - On 18–20 February 2019, the World Health Organization (WHO) agreed on the recommended composition of the quadrivalent influenza vaccine for the northern hemisphere 2019–2020 influenza season: an A/Brisbane/02/2018 (H1N1)pdm09-like virus, an A(H3N2) virus component to be announced on 21 March 2019, a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) and a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).